GreenLight Biosciences Holdings

GRNANASDAQHealthcare

$0.30

$-0.00(-0.03%)

Market Cap$45428456

P/E Ratio—

52W High$5.9

52W Low$0.177

Avg Volume713K

Open$0.30

Beta1.44

Overview

GreenLight Biosciences Holdings (GRNA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

grna · stock forecast · 2 analysts (3M) · FMP · updated Sep 16, 2024

Analyst Rating & Consensus

Based on 2 Wall Street analysts in the past 3 months

Buy

2 analysts

consensus

Rating Breakdown

Strong Buy

Buy

Hold

Sell

Strong Sell

Total: 2 · Buy rate: 50.0%

12-Month Price Target

High

$18.00

Consensus

$11.00

+3572.8% upside

Low

$4.00

Median: $11 · Last Close: $0.30

The GreenLight Biosciences Holdings (GRNA) analyst consensus is Buy, based on ratings from 2 Wall Street analysts over the past 3 months. The average 12-month GRNA price target is $11.00, representing +3572.8% upside from the current price of $0.30.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Analyst price target coverage is insufficient to generate a forecast chart for this stock.

Short-Term Price Prediction

Low Activity

Algorithmically generated · Updated daily

Date	Predicted Price	Change	Min	Max
2026-06-10	$0.30	↑ 0.22%	$0.30	$0.30

1-day model range: $0.3–$0.3. Peak: $0.3 (+0.22%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)55.2

MACDBULLISH

Moving Averages · GRNA · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$0.30BUY

MA 10$0.30BUY

MA 20$0.30BUY

MA 50$0.00NEUTRAL

MA 100$0.00NEUTRAL

MA 200$0.00NEUTRAL

Current $GRNA · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$0.30BUY

EMA 10$0.30BUY

EMA 20$0.30BUY

EMA 50$0.00NEUTRAL

EMA 100$0.00NEUTRAL

EMA 200$0.00NEUTRAL

Current $GRNA · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:

Date	Brokerage	Action	Rating
2023-05-31	Canaccord Genuity	Downgrade ↓	Buy→Hold
2023-05-30	Canaccord Genuity	Downgrade ↓	Buy→Hold
2022-12-08	Canaccord Genuity	Maintains	Buy→Buy
2022-10-14	Credit Suisse	Maintains	Outperform→Outperform

Canaccord Genuity2023-05-31

Downgrade ↓

Buy→Hold

Canaccord Genuity2023-05-30

Downgrade ↓

Buy→Hold

Canaccord Genuity2022-12-08

Maintains

Buy→Buy

Credit Suisse2022-10-14

Maintains

Outperform→Outperform

Wall Street analysts have recently issued updated ratings on GreenLight Biosciences Holdings (GRNA) stock. Of the recent 4 rating actions, 0 were upgrades and 2 were downgrades. 2 analysts currently cover GRNA.

Analyst Recommendation Trends

Buy ratings1 → 0↓ 1

Hold ratings0 → 2↑ +2

Sell ratings0 → 0

GRNA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

—

Revenue Next Year

—

EPS This Year

—

EPS Next Year

—

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast GRNA EPS of $— for the current fiscal year, based on estimates from 0 analysts. The GRNA revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The GRNA stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GRNA price target is $11.00 (+3572.8% upside), with an analyst consensus of Buy.

The GRNA short-term stock prediction for tomorrow is $0.30 (+0.22%).

GreenLight Biosciences Holdings trades on NASDAQ under the ticker GRNA. The GRNA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Earnings Revenue PE Ratio Financials Market Cap Insider Trades Dividends Price History

Frequently asked questions

GRNA forecast · 8 questions

According to 2 Wall Street analysts, the average 12-month GRNA price target is $11.00, with a high forecast of $18.00 and a low of $4.00. The median price target is shown in the chart above when available. This implies +3572.8% potential upside from the current price of $0.30.

GRNA price targetWhat is GRNA price targetGRNA analyst price targetGRNA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.